Ask AI
ProCE Banner Activity

PBC in the Real World: Recent Evidence for Second-line PPAR Agonists

Clinical Thought

Real-world evidence with PPAR agonists in PBC is not only confirming what we observed in clinical trials, but it is also expanding our understanding of how these therapies perform in more diverse and complex populations. 

Released: June 19, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity is intended for physicians, including hepatologists and gastroenterologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals involved in the care of patients with PBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate emerging data regarding best practices for management of patients with PBC

  • Utilize emerging data to improve treatment plans for patients with PBC

  • Integrate expert guidance and patient insights into treatment plans for PBC

Financial Disclosures

Primary Author

Maria Londono, MD, PhD: consultant/advisor/speaker: Advanz, Gilead, GSK, Ipsen, Mirum.